Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

NCT04149275 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding withdrawn by sponsor

Conditions

Carcinosarcoma of Ovary
Carcinosarcoma of Uterus
Carcinosarcoma of Vagina

Interventions

DRUG: Cabozantinib
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

University of Alabama at Birmingham